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ABSTRACT 
Background: Previous studies indicate that early symptomatic improvement, typically 
observed during the first 4 weeks of psychological therapy, is associated with positive 
treatment outcomes for a range of mental health problems. However, the replicability, 
statistical significance and magnitude of this association remains unclear.  
Aim: The present study reviewed the literature on early response to psychological 
interventions for adults with depression and anxiety symptoms.  
Methods: A systematic review and random effects meta-analysis was conducted, including 
studies found in Medline, PsychINFO, SCOPUS, Web of Science, and through reference lists 
and reverse citations.  
Results: Twenty-five eligible studies including 11091 patients measured early response and 
examined associations with post-treatment outcomes. It was possible to extract and/or 
calculate effect size data from 15 studies to conduct a meta-analysis. A large pooled effect 
size (g = 0.87 [95 % CI: 0.63, 1.10] p < .0001) indicated that early responders had 
significantly better post-treatment outcomes compared to cases without early response, and 
this effect was larger in anxiety (g = 1.37) compared to depression (g = 0.76) measures. Most 
studies were of good quality and there was no evidence of publication bias. The main 
limitations concerned insufficient statistical reporting in some studies, which meant that the 
meta-analysis only included 60% of reviewed studies, and it was not possible to examine 
effect sizes according to different outcome questionnaires.  
Conclusions: There is robust and replicated evidence that early response to therapy is a 
reliable prognostic indicator for depression and anxiety treatment outcomes. 
Key words: early response; psychological therapy; depression; anxiety 
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1. INTRODUCTION 
Symptomatic improvements that occur during the initial sessions of psychological therapy, 
and which are of a statistically and/or clinically significant magnitude, have been termed 
early response. As early as the 1980s, psychotherapy researchers have observed that the bulk 
of symptomatic improvement occurs within the first month of therapy, with 60% of total 
improvement in cognitive behavioural therapy for depression occurring by week four (Rush, 
Kovacs, Beck, Weissenburger, & Hollon, 1981). Since then, numerous other studies have 
reported early response patterns across different mental health problems and psychological 
therapies (Bell, Waller, Shafran, & Delgadillo, 2017; Bradford et al., 2011; Delgadillo et al., 
2014; Doyle, Grange, Loeb, Doyle & Crosby, 2009; Gois et al., 2014; Hunnicutt-Ferguson, 
Hoxha & Gollan, 2012; Rubel et al., 2015).  
Some studies have found that early symptomatic response is associated with better 
post-treatment outcomes (e.g., Crits-Christoph et al., 2001; Grilo, Masheb & Wilson, 2006; 
Lutz et al., 2017; Stauffer et al., 2011; van Calker et al., 2009). However, the magnitude of 
this association varies considerably across studies and clinical samples. For example, in 
samples of patients accessing guided self-KHOSIRUGHSUHVVLRQ7DGLüHWDOUHSRUWHGDQ
odds ratio of 1.33 whereas Delgadillo et al. (2014) reported an odds ratio of 12.60. 
Furthermore, others have found mixed results. For example, Arnow et al. (2007) found no 
significant associations between early response and treatment dropout.  %DúR÷OXHWDO (1994) 
found that early response predicted some post-treatment outcomes (panic attacks) but not 
others (anticipatory avoidance). In addition, there is still no agreed-upon time scale of when 
early response occurs by in psychological therapy (Haas, Hill, Lambert & Morrell, 2002; 
Rubel et al., 2015). For example, some studies have shown that this can happen by week two 
or three, whilst others have examined this by week eight or later (Arnow et al., 2007; Bell et 
al. 2017; 5XEHOHWDO7DGLüHWDO$lso, different psychological therapies have 
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varying numbers of sessions within the first month of treatment. For example, Tang and 
DeRubeis (1999a) state that there are not always four sessions within the first month of 
cognitive behavioural therapy (CBT); instead, in treatment lasting around 12 to 20 weeks, 40 
to 60% of sessions occur within the first month. Studies assessing early response are also 
heterogeneous, since they use different symptom measures and baseline levels of distress 
differ among study samples.  
Therefore, whilst it appears to be that people with early symptomatic improvements 
tend to have a better prognosis, the replicability, statistical significance and magnitude of the 
association between early response and post-treatment outcomes remains unclear. The current 
systematic review aimed to synthesise what is known about the association between early 
response and psychological treatment outcomes in adult patients seeking treatment for 
depression and anxiety. 
 
2. METHODS 
2.1. Protocol and Registration 
The review protocol was prospectively registered in the PROSPERO database 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018089123). 
2.2. Search Strategy and Study Selection 
Table 1 specifies the inclusion and exclusion criteria that guided this review. Four databases 
were searched in order to search for titles, abstracts and key words (Appendix A) on February 
13, 2018: Medline, PsychINFO, SCOPUS and Web of Science. The search was limited to 
peer reviewed articles or book chapters published in English. No date restrictions were 
applied. A full list of excluded studies and reasons for exclusion are listed in Appendix B. 
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7KHVHDUFKDOVRLQFOXGHGWKHWHUPV³VXGGHQJDLQV´ZKLFKFDQEHGHILQHGDVsudden 
and statistically significant symptomatic improvements that occur between two consecutive 
sessions during therapy (Tang & DeRubeis, 1999b). Although sudden gains are conceptually 
different to early response (which can be gradual and over more than two sessions), sudden 
gains that occur early in treatment can overlap with and contribute to an early response 
pattern. Therefore, studies where the median sudden gain session occurred within the first 
four weeks of therapy were also included; consistent with evidence that most sudden gains 
occur within the first month (e.g., Tang & DeRubeis, 1999a). Titles and abstracts were 
screened by the first author, followed by a full-text review. Of the studies eligible for the 
review, reverse-citations and reference list searches were conducted by hand to identify 
further eligible studies. A PRISMA diagram summarising the study selection process is 
presented in Figure 1. 
 
[Table 1] 
 
[Figure 1] 
 
2.3. Quality and Risk of Bias Assessment 
Two reviewers independently assessed the quality and risk of bias for each study using the 
Quality Assessment Tool for Observational Cohort and Cross-sectional Studies and the 
Cochrane Handbook for Systematic Reviews of Interventions for Controlled Trials (Higgins, 
Altman & Sterne, 2017). Quality ratings were highly consistent and did not require mediation 
by a third reviewer. See Appendix C for quality assessment summary tables. 
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2.4. Data Analysis  
In addition to a narrative synthesis of all reviewed studies, a random effects meta-analysis 
was conducted using the statistical package Meta-Analysis via Shiny (MAVIS; Hamilton, 
2011). Studies that examined the predictive value of early response and which reported 
sufficient statistical information to calculate standardised effect sizes were included in the 
meta-analysis. Hedges g was calculated to adjust for unequal sample size across groups, 
comparing post-treatment outcomes between early responders versus cases without early 
response. Heterogeneity was examined using the Q and I2 statistics (Higgins et al., 2003). 
Potential publication bias was examined using a weight-function model (Vevea & Hedges, 
1995) as well as the fail-VDIH1FDOFXODWLRQXVLQJ5RVHQWKDO¶VPHWKRGRosenthal, 1991).   
There were several sources of heterogeneity in the design of the studies, including in 
the symptom measures used, the time-point at which early response was defined, and the 
time-point at which outcomes were assessed (e.g. post-treatment, at 6-months follow-up). We 
therefore followed a principled and consistent approach to enable meta-analysis, where we 
selected the outcome measure with the largest effect size (in studies with multiple outcomes), 
at the measurement point closest to session 4 (in studies with multiple measurements), with 
the outcome defined at the end of treatment (or most proximal follow-up assessment). In a 
subgroup analysis, we separately meta-analysed samples using measures for depression or 
anxiety symptoms. Other sources of heterogeneity such as differences in the types of 
treatments and study design were examined by removing systematically different studies 
from the meta-analysis and examining the influence on pooled effect sizes and indices of 
heterogeneity. The small number of studies (<20) that were included in meta-analysis and the 
imbalance in the number of studies per each of the above categories of heterogeneity 
precluded the use of categorical moderator analysis, according to conventional guidelines 
(5XELRဨ$SDULFLR6iQFKH]ဨ0HFD/ySH]ဨ/ySH]%RWHOOD	0DUtQဨ0DUWtQH]).  
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[Table 2] 
 
3. RESULTS 
3.1. Study characteristics  
Design and sample characteristics. Twenty-five studies met the inclusion criteria and are 
described in Tables 2 and 3, including analyses of controlled trials (n= 16) and observational 
studies (n= 9). Many studies focused exclusively on depression (n= 16), whilst only three 
focused exclusively on anxiety disorders. Sample sizes ranged from 23 to 5484 participants, 
with nearly all of the studies including more females than males.  
Measures. A wide range of measures were used to assess early response, as shown in 
Table 2. The Beck Depression Inventory (BDI) and the Hamilton rating scale for depression 
(HAMD) were most commonly used to assess depression symptoms. A variety of different 
measures were used to assess anxiety, including the Beck Anxiety Inventory (BAI), Penn 
State Worry Questionnaire, and Panic Disorder Severity Scale-self report. Measures of 
psychological distress included the Outcomes Questionnaire (OQ-45), and the Clinical 
Outcomes in Routine Evaluation (CORE). Only two studies used general psychological 
distress measures rather than disorder-specific measures to assess symptom change (Lutz et 
al., 2017; Rubel et al., 2015), whilst two used a combination of both (Lutz, Stulz & Köck, 
2009; Schibbye et al., 2014). 
Defining early response. Many studies conceptualised early response by quantifying 
changes between intake assessments and week four of treatment, as reported by 15 of the 25 
studies, while others conceptualised this as far as the 8th week. Sixteen studies used standard 
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and similar criteria to define early response, including reliable change (RC; Jacobson & 
Traux, 1991) a specific percentage reduction on the measures used (e.g., >25% reduction of 
symptom severity from baseline to the week of early response), or early remission of 
symptoms based on established diagnostic cut-off scores. Other studies defined early 
response using methods such as hierarchical agglomerative cluster analysis (HAC) or Growth 
Mixture Modelling (GMM) to identify different trajectories of change among participants. 
The three studies measuring sudden gains used Tang aQG'H5XEHLV¶EGHILQLWLRQand 
each study modified the criteria to fit the measures used and the diagnosis of patients. With 
regards to the relationship between early response and outcomes, 18 of the 25 studies clearly 
stated the methods used to predict outcomes among early responders.  These methods 
included receiver operating characteristic curves (ROC), logistic regression, general linear 
models (GLM), GMM, trajectory analysis, linear modelling of growth curves, cluster 
analysis, piecewise growth mixture modelling (PGMM) and HAC. 
Interventions. Most of the studies focused solely on psychological interventions (n= 
15), where cognitive behavioural therapy (CBT) was the most commonly studied 
intervention. Ten studies included samples that accessed either pharmacotherapy or 
psychological therapy (both treatments were combined in 3 of these studies). 
Of the studies using exclusively psychological therapies, two used internet-based 
cognitive-behavioural therapy, one used group telephone therapy, and another pooled data for 
patients who accessed individual, group and internet-delivered therapies. Other psychological 
therapies included cognitive behavioural analysis system of psychotherapy (CBASP), 
supportive-expressive dynamic psychotherapy, interpersonal psychotherapy (IPT), 
behavioural activation, metacognitive therapy, short-term psychodynamic supportive 
psychotherapy (SPSP), behavioural therapy and self-control therapy. Thirteen studies used a 
variety of psychological or pharmacological treatments but not all of them provided 
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information about each type of therapy, and the different therapies were not all analysed 
separately. 
3.2. Quality Assessment 
Overall, most reviewed studies had low risk of bias. More than half (15 = 60%) were rated as 
³JRRG´TXDOLW\VWXGLHVDQGDIXUWKHUZHUHUDWHGDV³IDLU´2QO\WZRZHUHUDWHGDV
³SRRU´TXDOLW\VWXGLHVZLWKKLJKULVNRIELDVThe most common sources of bias included the 
failure to report dropouts / excluded cases, lack of recruitment information, little or no 
description of treatments, and lack of information about randomization procedures and 
blinding in clinical trials. A detailed risk of bias assessment for each study can be found in 
supplementary Appendix C.  
3.3. Early response and treatment outcomes 
Pooling available data across studies indicated that approximately half (47.9%) of study 
participants were classified as early responders. The majority of these studies found support 
for a positive association between early response and post-treatment outcomes as summarised 
in Table 3. Some studies additionally investigated the influence of pre-treatment changes that 
may have occurred prior to exposure to therapy (e.g., between intake assessments and the 
first therapy session). These studies found that early response to therapy remained a 
significant predictor after controlling for pre-treatment changes that might denote regression 
to the mean (Delgadillo et al., 2014; Lutz et al., 2017). Furthermore, early response was 
associated with clinical outcomes across different severities of psychological distress (e.g., 
mild, moderate, severe depression), different forms of psychotherapy / pharmacotherapy and 
even in a placebo control group (see: 7DGLü et al., 2010). 
Only one study did not support an association between early response and outcomes, 
although they specifically focused on dropouts (Arnow et al., 2007). Two studies found 
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HTXLYRFDOUHODWLRQVKLSVEHWZHHQHDUO\UHVSRQVHDQGSRVLWLYHRXWFRPHV%DúR÷OXHWDO
found no association between early remission in panic symptoms and improvement in 
anticipatory anxiety and avoidance at post-treatment. However, they did find an association 
between early improvement in phobia symptoms and a reduction in panic attacks. Van et al. 
(2008) compared psychological therapy with a combination of pharmacotherapy and 
psychotherapy. In the psychotherapy condition, early non-response significantly predicted 
final non-response. However, this was not the case for remission rates. In the combined 
therapy condition, both final non-response and remission rates differed significantly for those 
who showed early non-response and early response. This may suggest that the medication in 
the combined therapy influenced the predictive value of early response. Therefore, the 
potential influence of combined treatments was examined using a subgroup meta-analysis 
described in the next section.  
Some of the reviewed studies did not specifically test early response ± outcome 
associations, but instead focused on when the largest changes occurred, how many cases 
showed early response, or which variables predicted early response (Gildengers et al., 2005; 
Heckman et al., 2017; Jordan et al., 2014; Rabin, Kaslow & Rehm, 1984). The key findings 
from these studies are summarised in Table 3. 
 
[Figure 2] 
 
3.4. Meta-analysis 
A primary meta-analysis was conducted using effect size data from 15 studies (including 18 
unique samples and 3956 participants) to examine associations between early response and 
post-treatment outcomes. The weighted mean effect size was g = 0.87 [95 % CI: 0.63, 1.10] p 
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< .0001, indicating that early responders had significantly better treatment outcomes 
compared to cases without early response (see Figure 2). &RFKUDQH¶V4-test revealed 
evidence of significant heterogeneity in the sample (Q(17) = 246.12, p < .0001) and the I2 
statistic was 87.73%, indicating a large degree of heterogeneity. The weight-function model 
likelihood ratio test did not indicate evidence of publication bias; x2(1) = 3.08, p = .08. 
Calculation of the fail-safe N indicated that 3200 studies with non-significant results would 
be needed to conclude that the effect of early response is not statistically significant. 
A series of subgroup analyses were conducted to examine the potential influence of 
methodological features. Removing samples (k = 6) with combined (psychotherapy and 
pharmacological) treatments, samples (k = 4) from studies that applied latent clustering of 
symptom trajectories, samples (k = 4) from studies that investigated sudden gains, and 
samples (k  IURPVWXGLHVZLWK³IDLU´LQVWHDGRI³JRRG´TXDOLW\UDWLQJVPDGHOLWWOH
difference to the pooled effect sizes (g = 0.82 to 0.92) and indices of heterogeneity (I2 = 
87.46 to 91.83%) obtained in subsamples. However, removing samples (k = 4) from 
observational studies considerably reduced the pooled effect size (g = .74) and indices of 
heterogeneity (I2 = 79.69%; Q(13) = 66.72, p < .0001) observed in the subgroup of RCT 
samples. Removing two studies (%DúR÷OXHWDO; Steinman et al., 2013) that specifically 
examined panic disorder interventions also considerably reduced the pooled effect size (g = 
.77) and indices of heterogeneity (I2 = 79.70%; Q(15) = 230.87, p < .0001) observed in the 
subgroup of RCT samples. Furthermore, separate meta-analyses in the samples analysing 
depression (k = 15, n = 3690) and anxiety (k = 5, n = 2214) measures revealed markedly 
different effect sizes (depression g = 0.76 [0.58, 0.94]; anxiety g = 1.37 [0.86, 1.88]) and 
indices of heterogeneity (depression I2 = 76.27%; anxiety I2 = 90.00%). Forest plots for these 
separate meta-analyses are shown in supplementary Appendix D. 
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4. DISCUSSION 
4.1. Summary of evidence  
This systematic review provides robust evidence of a positive association between early 
response to psychological therapy and post-treatment outcomes. A large and statistically 
significant overall effect size (g = 0.87) indicated that early responders tended to have better 
treatment outcomes compared to other patients. Translating this effect size into an odds ratio 
scale (4.84), would indicate that early responders were at least four times more likely to attain 
positive treatment outcomes compared to other cases. This association was replicated across 
various forms of therapy including CBT, psychodynamic and interpersonal psychotherapies, 
and guided self-help interventions delivered in person, in groups, via telephone and via 
internet. Furthermore, there was low risk of bias in most of the reviewed studies, which were 
generally of good methodological quality, and we found no evidence of publication bias. 
The effect of early response on anxiety outcomes was considerably larger (g = 1.37) 
compared to the effect on depression outcomes (g = 0.76). However, the index of 
heterogeneity for anxiety studies was much higher (I2 = 90% vs. 76%), suggesting that the 
influence of early response may vary across anxiety disorders. In particular, large effect sizes 
(g = 1.80 to 1.87) were observed in the studies that examined early response to panic disorder 
treatments (%DúR÷OXHWDO; Steinman et al., 2013), and the exclusion of these two 
studies reduced the overall heterogeneity of meta-analytic findings. The design of studies was 
another relevant source of heterogeneity, as we found that the index of heterogeneity was 
somewhat attenuated in the subsample of randomised controlled trials (after excluding 
observational studies). This is plausibly explained by the stringent inclusion/exclusion criteria 
applied in clinical trials, which typically yields more diagnostically homogeneous samples 
compared to naturalistic observational studies.  
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4.2. Methodological Considerations  
The studies included in this review varied considerably in the methods used to assess early 
response. For example, Rubel et al. (2015) compared three different approaches: growth 
mixture modelling (GMM), reliable change (RC) and clinical improvement. They found that 
at session three approximately 35% of the participants met criteria for RC, and 16.3% had 
achieved clinically significant improvement. On the other hand, when using GMM, only 
7.2% showed early positive response by session three. This shows that GMM is a more 
conservative approach, identifying much fewer patients as showing early response than the 
RC and clinical improvement methods. This was also found when comparing the studies by 
Gilboa-Shechtman and Shahar (2006) and Lutz et al. (2009) which re-analysed the same 
dataset (Elkin et al., 1989). Although both studies included the same number of participants 
from the same dataset, they used different methods to identify early response and to predict 
outcomes. Consistent with Rubel et al. (2015), Lutz et al. (2009) identified fewer patients as 
showing early response (n=99) when using GMM, compared to Gilboa-Shechtman and 
Shahar (2006) who used linear modelling of growth curves (n=122). 
Early response was most often defined by week 4, although other cut-offs were used 
in different studies. For example, Steidtmann et al. (2013) used weeks four, six and eight as 
they are considered to be clinically useful decision points. Similarly, Schibbye et al. (2014) 
used week five as it represented the first half of the treatment. The studies by Arnow et al. 
(2007), %DúR÷OX et al (1994) and 7DGLü et al. (2010) defined early response by week two of 
treatment. Alternatively, some studies retrospectively identified a week of early response via 
the use of statistical methods that modelled latent trajectories of change (e.g., Heckman et al., 
2017; Lutz et al., 2009; Steinman et al., 2012). In spite of these methodological differences, 
subgroup analyses removing latent trajectory profiling studies from meta-analysis did not 
considerably change the pooled effect size or indices of heterogeneity. However, Rubel et al. 
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(2015) argue that a minimum of three sessions are required to conduct GMM, suggesting that 
there may not have been enough information within the first two weeks of treatment to assess 
the predictive value of early response. Therefore, it may be that week two is too early to find 
significant differences between those who do and do not show early response, which may 
possibly explain the mixed results found by Arnow et al. (2007), %DúR÷OX et al (1994) and 
7DGLü et al. (2010). Overall, studies that defined early response by week four or later 
consistently found associations with post-treatment outcomes. 
In total, only 10 of the 25 (40%) studies clearly stated how they handled missing data 
in their analyses. Not appropriately managing dropouts can lead to biased interpretations of 
results (Dumville, Torgerson & Hewitt, 2006; Mallinckrodt et al., 2001). Therefore, it may be 
that including and examining all participants who dropped out of treatment could potentially 
influence the results concerning early response and treatment outcomes. However, reviewed 
studies that used an intention-to-treat approach still found large and statistically significant 
effects of early response over treatment outcomes.  
4.3. Strengths and limitations 
To our knowledge, this is the first meta-analytic review to assess the association between 
early response and psychological therapy outcomes. Strengths of this review include the 
prospective registration of the review protocol and the study selection across multiple 
databases, which had no date restriction in order to gather all eligible studies. Reverse and 
forward citation searches were also conducted. The review also included a quality assessment 
by two independent assessors. However, the review excluded grey literature, studies 
published in languages other than English, and authors of eligible studies were not contacted 
to request data.  
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Some limitations should be taken into account when interpreting the findings of this 
review. Due to such a wide variety of measures and methods used to assess early response, 
directly comparing findings was difficult. Although a series of subgroup analyses were 
carried out, there was still a large amount of heterogeneity left unexplained. This is likely to 
have been due to the large number of measures used across the studies, with only two studies 
in the meta-analysis using the same depression measure. This meant that a subgroup analysis 
to assess the effect of specific measures was not possible. We also note that only 60% of 
reviewed studies provided sufficient information to compare treatment outcomes between 
cases with and without early response. In spite of the limited number of studies that 
contributed to meta-analysis, there was no evidence of publication bias and the fail-safe N 
(3200) indicated that the meta-analytic results were robust. 
Sudden gains that occur early in treatment arguably overlap with the early response 
phenomenon. On this basis, we imposed inclusion criteria to ensure that we only analysed 
data from studies where the median sudden gain session occurred by week 4. This a priori 
exclusion criterion resulted in a stricter exclusion of sudden gains studies and a more liberal 
inclusion of early response studies. We argue that this is appropriate, given the focus of the 
current review. A more liberal inclusion of sudden gains studies would risk confounding 
these constructs, making it difficult to ascertain whether or not early response predicts better 
treatment outcomes (over and above the already known effect of sudden gains). We note that 
a subgroup analysis excluding sudden gains studies made no difference to the pooled meta-
analysis results, so the inclusion of these studies is unlikely to bias results in any way. 
Whilst the inclusion of RCTs and observational studies allowed for the inclusion of a 
greater number of studies, there are limitations in both designs. Observational studies have 
the advantage of including patients who are encountered in routine practice, thus 
strengthening the external validity of results. However, internal validity can be compromised 
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in observational studies, since they often lack rigorous features that are present in RCTs, such 
as the use of control groups, randomisation and blinding, adherence to treatment manuals, 
and stringent inclusion and exclusion criteria. RCTs included in this review also varied 
considerably in their patient selection criteria and how well they handled missing data. 
Although the study design accounted for a proportion of heterogeneity (as described above), 
it is nevertheless clear that early response is a phenomenon that occurs across a wide variety 
of study designs and settings. Another point to consider is that a large number of secondary 
analyses were included in the review. These studies should be interpreted with caution as 
secondary analyses can lack statistical power and multiple testing can inflate the chances of 
type 1 error. 
4.4. Implications for research, theory and practice  
It is important to consider the findings of this review in the context of previous research. 
Although sudden gains are conceptually different from early response, unless they occur by 
week four of therapy, they are both important for predicting post-treatment outcomes. A 
meta-analysis conducted by Aderka, Nickerson, Bøe and Hofmann (2012) found results 
consistent with the current review. They found robust evidence for a positive association 
between sudden gains and primary outcomes in depression and anxiety symptoms. However, 
whilst the current review focused on primary symptoms of depression and anxiety, Aderka et 
al. (2012) also examined secondary symptoms. Compared to the large effect size in primary 
symptoms (g=0.62, [0.43, 0.80]), the effect size for secondary symptoms was small and non-
significant (g=0.37, [-0.34, 1.07]). This suggests that sudden gains in primary symptoms may 
not necessarily lead to improvements in secondary symptoms. As the current review did not 
address this, future research or reviews into early response should also focus on secondary 
symptoms. Secondly, Aderka et al. (2012) found effect sizes of sudden gains to be much 
larger in CBT interventions compared to non-CBT interventions. Only eight of the 25 studies 
17 
 
in the current review used therapies other than some form of cognitive therapy. This 
highlights the need for more research into early response in treatments other than cognitive 
therapies. Additionally, Aderka et al. (2012) found no differences in effect sizes across 
depression and anxiety, while the present review indicates a stronger influence of early 
response on anxiety outcomes compared to depression.  
Previous authors have suggested that the early response effect could be explained by a 
trend of improvement that began prior to the start of treatment, which might be indicative of 
regression to the mean (Beckham, 1989). Two of the reviewed studies did in fact observe that 
early pre-treatment gains are associated with trajectories of improvement, however both 
studies still found significant effects of early response during treatment after controlling for 
pre-treatment gains (Delgadillo et al., 2014; Lutz et al., 2017). On this basis, the effect of 
early response cannot be entirely explained by regression to the mean. Furthermore, the 
pooled rate of early response across studies (47.9%) was considerably higher than the rate of 
short-term remission observed in waitlist control groups (~20%) of depression treatment 
trials (Posternak & Miller, 2001; Whiteford et al., 2013); hence the early response effect 
cannot simply be explained by spontaneous remission.  
An alternative explanation could be derived from the findings by 7DGLü et al. (2010), 
which indicated that individuals in a placebo control group also experienced early response at 
an equal or higher rate than the CBT group and with similar effects on the eventual remission 
of symptoms. This could potentially be explained by the nonspecific factors discussed by 
Ilardi and Craighead (1994), who suggest that early response may simply be due to a 
³UHDGLQHVVWRFKDQJH´DQGLVWKHUHIRUHDTXDVL-placebo response to factors such as increased 
hope and expectations of improvement. Howard et al. (1993) have previously referred to this 
as a remoralisation effect which they attributed to common factors that are likely to be 
present in most forms of psychotherapy. This explanation fits within the wider literature on 
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the placebo effect in healthcare. For example, prior studies have shown experimentally that 
perceiving clinicians as warm, friendly, empathic and competent enhances the placebo effect 
(Howe, Goyer, & Crum, 2017; Kaptchuk et al., 2008). However, given that the four other 
studies in this review using a control condition either only reported early response in the 
treatment condition or pooled the data, it was not possible to determine whether early 
response occurs consistently across the placebo conditions. Future individual patient data 
meta-analyses of trials comparing psychotherapies with placebo could help to elucidate the 
extent to which the early response phenomenon may be partly or fully explained by a quasi-
placebo effect. 
An important clinical implication of this literature is that response to treatment during 
the first month is a reliable prognostic indicator across multiple forms of psychological care 
for common mental health problems. The fourth session could be seen as a timely 
opportunity to review treatment outcomes and to identify potential obstacles to improvement, 
which is consistent with the principles of routine outcome monitoring and feedback-informed 
treatment (Carlier et al., 2012; Lambert et al. 2003). 
4.5. Conclusions 
In conclusion, a robust evidence-base supports the notion that patients showing reliable 
symptomatic improvements within the initial therapy sessions tend to have a much better 
prognosis after treatment. Therefore, routinely monitoring early response is of paramount 
importance, as it has the potential to identify those who may have a protracted or limited 
response to treatment. A clinical review using validated outcome measures at the fourth 
session of therapy is recommended, in order to assess progress and to identify potential 
obstacles to improvement in cases that have not yet shown reliable symptomatic 
improvements.  
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Table 1. Inclusion and exclusion criteria 
 Review question  
 Does early response to psychological therapy predict post-treatment depression or anxiety outcomes? 
 Inclusion criteria Exclusion criteria 
Population Adult patients 18 years and over accessing psychological 
interventions for anxiety (including Obsessive-Compulsive Disorder, 
Post-Traumatic Stress Disorder, other anxiety disorders) and/or 
depression. 
Studies exclusively with children and/or adolescents under 18. 
Studies exclusively with non-clinical samples. 
Intervention Any form of psychological therapy or intervention with the aim of 
treating depression or anxiety and delivered in any modality 
(individual, group, internet-based etc.).  
Studies that do not include psychological interventions for depression 
and/or anxiety. 
Comparator  A between-groups comparison of those who do and do not show 
early response to psychological therapy.  
Studies comparing treatment outcomes between cases that had 
sudden gains early in treatment (e.g. sample median sudden gain 
occurred within the first 4 weeks) and cases without sudden gains. 
Studies where no comparisons are made between cases with and 
without early response to psychological treatment. 
Studies where sudden gains tended to occur after the fourth week of 
therapy. 
Outcomes The statistical significance and magnitude of the association between 
early response and post-treatment depression and anxiety outcomes.  
Studies where early response is not measured. 
Studies where post-treatment depression / anxiety outcomes are not 
reported. 
Setting Any settings where psychological interventions are usually delivered, 
including online or telephone therapy, in any country.  
 
Study design  Randomised controlled trials and observational studies. 
Studies published in peer reviewed scientific journals, in the English 
language. 
Grey literature, such as dissertation theses, which are not published in 
peer reviewed scientific journals. 
Editorials, newspaper or magazine articles and other forms of media. 
Literature sources not in published in English. 
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Table 2. Characteristics of studies included in the review 
First Author and Year Study Design Study Setting Primary Disorders Analysed 
N 
Intervention 
Condition 
Outcome 
Measuresj 
Intervention 
Duration 
Arnow et al. (2007) RCTb NA MDD 681 CBASP, 
Nefazadone or 
COMBh 
HAMD-24 12 weeks 
%DúR÷OXHWDO. (1994) RCTb UK and US, 2 
outpatient sites 
PD, agoraphobia  154 AE, PE, AR or PR Main phobia 
targets: avoidance 
and feark 
8 to 16 weeksl 
Beckham. (1989) Observational  US, university-based 
research site 
Depression 23 CBT BDI NA 
Bradford et al. (2011) RCTb US, Primary care 
clinic 
GAD 76 CBT PSWQ 12 weeks 
Braun et al. (2015) Observationalc NA Depression  55 CT BDI-II, HRSD 16 weeks 
Crits-Christoph et al. 
(2001) 
 
RCTb NA Mixede 98g CT, SE  BDI, BAI 16 to 52 
weeksm  
Delgadillo et al. (2014) Observationalc UK, 1 primary care 
mental health service 
 
Mixede 1850 LiCBT PHQ-9, GAD-7 Up to 10 
weeks 
Dew et al. (1997)a Observationalc US, psychiatric 
institute and clinic 
Depression 95 Combined NT and 
IPT 
HAMD-17 18 weeksn 
Gilboa-Schechtman et al. 
(2006) 
 
RCTb  US, 3 university 
research sites 
MDD 162 CBT, IPT, IMI-
CM or PLA-CM 
BDI, HRSD 16 weeks 
Gildengers et al. (2005)a RCTb US, university based 
research site 
MDD 395 IPT, NT or PX HRSD-17 12 weeks 
Gois et al. (2014) RCT Portugal, 3 outpatient 
diabetes clinics 
MDD 30 IPT or Sertraline MADRS 24 weeks 
Heckman et al. (2017) RCTb US, telephone based Depression 103 Group 
Teletherapy 
GDS 12 weeks 
Hunnicutt-Ferguson et 
al. (2012)a 
 
Observational NA MDDf 42 BA QIDS-SR 16 weeks 
Jordan et al. (2014) RCT pilot study  NZ, university clinical 
research unit 
MDD, Bipolar II 48 MCT vs CBT QIDS 16-C 12 weeks 
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Lewis et al. (2012) Observational  US, university training 
clinic 
Mixede 173 CBT BDI NA 
Lutz et al. (2009) RCTb US, 3 university 
research sites 
MDD  162 CBT, IPT, IMI-
CM or PLA-CM 
BDI, HSCL-90 16 weeks 
Lutz et al. (2017) RCT Internet-basedd Depression  409 ICBT PHQ-9 12 weeks 
Masterson et al. (2014) RCTb UK, mental health 
practices 
Depression 40 BA PHQ-9 12 weeks 
Rabin et al. (1984) RCT NA Depression  98 BT, CT or CBT 
and Self-Control 
Group Therapy 
BDI 10 weeks 
Rubel et al. (2015) Observational  Germany, 26 
counselling, medical 
or mental health sites 
Mixede 5484 Psychotherapyi GMH Not fixedo 
Schibbye et al. (2014) Observational Sweden, intenet-based Mixede 112 ICBT OQ-45, CORE-
10, MADRS-S, 
PDSS-SR, LSAS-
SR 
10 weeks or 
15 weeksp 
Steidtmann et al. (2013) RCTb Outpatient sitesd MDD 352 CBASP or 
COMBh 
IDS-SR 12 weeks 
Steinman et al. (2013) Observationalc  US, university 
research clinic 
PD 36 CBGT PDSS 12 weeks 
7DGLüHWDO RCTb Germany, outpatient 
facility 
Depression 223 Sertraline or CBT HAMD-17 10 weeks 
Van et al. (2008) RCTb Netherlands, 2 
outpatient facilities  
Depression 190 SPSP or SPSP 
with FX or VX 
HAMD-17 16 weeks 
RCT, randomised control trial; NA, not available; UK, United Kingdom; US, United States; NZ, New Zealand; MDD, major depressive disorder; PD, panic disorder; GAD, generalised anxiety disorder;  
CBASP, cognitive behavioural analysis system of psychotherapy; AE, alprazolam plus exposure; PE, placebo plus exposure; AR, alprazolam plus relaxation; PR, placebo plus relaxation; CBT, cognitive 
behavioural therapy; LiCBT, low intensity CBT (guided self-help); CT, cognitive therapy; SE, supportive-expressive dynamic psychotherapy; NT, Nortriptyline; IPT, interpersonal psychotherapy; IMI-CM, 
imipramine plus clinical management; PLA-CM, placebo plus clinical management; PX, Paroxetine; BA, behavioural activation; MCT, meta-cognitive therapy; ICBT, internet cognitive behavioural therapy; BT, 
behavioural therapy; CBGT, cognitive behavioural group therapy; SPSP, short-term psychodynamic supportive psychotherapy; FX, Fluoxetine; VX, venlafaxine; HAMD, Hamilton rating scale for depression; 
BDI, Beck depression inventory; PSWQ, Penn state worry questionnaire; HRSD, Hamilton rating scale for depression; BAI, Beck anxiety inventory; MADRS, Montgomery-Åsberg depression rating scale; GDS, 
geriatric depression scale; QIDS-SR, quick inventory of depressive symptomatology-self report; QIDS-C, quick inventory of depressive symptomatology-Clinician assessed; HSCL, Hopkins symptom checklist; 
PHQ, patient health questionnaire; GMH, general mental health; OQ, outcomes questionnaire; CORE, clinical outcomes in routine evaluation; PDSS-SR, panic disorder severity scale-self report; LSAS-SR 
Liebowitz social anxiety scale-self report; IDS-SR; inventory of depressive symptomatology-self report; SG, sudden gain.  
aOpen trial studies, therefore the participants and therapists were not blind to treatment conditions. 
bRCT refers to a secondary analysis of RCT.  
cObservational refers to a secondary analysis of observational studies.  
dCountry of study not reported  
eMixed refers to a variety of depression and anxiety disorders. 
fHealthy controls were also enrolled to take part in the study 
gHere we report the largest sample reported by the authors, which was used to investigate the predictive value of early response. 
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hCOMB refers to the psychotherapy used and the medication used combined  
iDoes not state what psychotherapy methods were used 
jOnly measures used to assess early response or early sudden gains  
kMain phobia targets were modified from Marks and Mathews (1979). Includes avoidance, self and assessor rated, and fear, self and assessor rated.  
lPsychological treatment lasted 8 weeks, medication could continue to week 16, 20 weeks for patients in the cross validation sample 
m16 weeks for depression or anxiety with 3 monthly booster sessions, 52 weeks for cases with avoidant or obsessive-compulsive personality disorder  
nThe authors focused only on the 18 weeks of therapy before randomisation (secondary analysis of RCT) 
oTreatment was not fixed to a strict time limit, sessions varied from 4 to 109 sessions (m=9.76, SD = 8.25) 
p10 weeks for depression and panic disorder, 15 weeks for social anxiety disorder  
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Table 3. Findings reported by studies included in the review 
First Author 
and Year 
Early 
Response 
Timingf  
N (% of total) Reported Statistics/Findings 
Early 
Responders 
Others 
Arnow et al. 
(2007) 
Week 2 NA NA No difference between dropouts and completers in terms of early response (main effect F=.33, 
p=.57; dropout x treatment F=.11, p=.89). 
 
%DúR÷OXHWDO
(1994) 
Week 2-4 NA NA Early improvement (by week 4) in avoidance of main phobia targets explained 45% of variance in 
clinical global impression (CGI) ratings by week 8. Week-4 improvement in fear explained 24% 
of variance in SDWLHQWV¶JOREDOLPSUHVVLRQ3*,UDWLQJVE\ZHHN. 
 
Beckham. 
(1989) 
Session 4-6 NA NA The BDI at session 6 correlated with the final session BDI (r=.80, p<.001). 
 
 
Bradford et 
al. (2011) 
Week 4 23 (30.3%) 53 Responders at 3 months had a significantly larger magnitude of change at 4 weeks compared to 
non-responders (t(74)=3.423, p<.001). This was the same for 15 month responders (t(74)=3.069, 
p=.003). 
 
Braun et al. 
(2015) 
Week 4 NA NA Symptom improvements from session 1 to 4 were significant and substantial (d=1.59, t=5.58, 
p<.001).  
 
Crits-
Christoph et 
al. (2001) 
Week 4 NA NA Change on the BDI and BAI measures from baseline to weeks 2, 3 and 4 significantly predicted 
remission at week 16 (all p<.005). At week 4, the Area under the curve (AUC) values for early 
change in each outcome measure were .73 for BDI and .77 for BAI. 
 
 
Delgadillo et 
al. (2014) 
 
Week 4 NA NA )RUSDWLHQWVZKRVHWUHDWPHQWODVWHGVHVVLRQVUHOLDEOHLPSURYHPHQWE\VHVVLRQSUHGLFWHG
post-treatment reliable and clinically significant improvement; with significant odds ratios in 
depression (pooled OR = 12.60, p < .001) and anxiety (pooled OR = 21.10, p < .001) measures. 
 
Dew et al. 
(1997) 
Week 4-6 29 (30.5%) 66 62% of the early response group already had below threshold HAMD scores by week 6. All 
subjects had these low scores by weeks 8-10. By week 4, early responders had a higher 
percentage of cases with remission of symptoms compared to non-early responders (x2 = 13.1, p < 
.01). 
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Gilboa-
Schechtman 
et al. (2006) 
 
Week 4 122 (75.3%) 40 The end of treatment BDI (F = 18.17, p < .01) and HRSD (F = 22.59, p < .01) scores were 
significantly lower for the rapid responders group compared to others.  
Gildengers et 
al. (2005) 
Week 2-5 181 (47.9%) 197 Early responders in NT+IPT reached HRSD score of 10 by week 5, PX+IPT by week 3 and 
NT/PX by week 2. 
 
Gois et al. 
(2014) 
Week 6 22 (73.3%) 8 Early responders showed significant improvement in depression over time in both IPT and 
Sertraline groups (F(2.4)=27.73, p<.001). 
 
Heckman et 
al. (2017) 
Week 4 32 (30.5%) 73 Post-treatment scores for early responders M=7.43, SD=4.2, delayed responders M=6.41, 
SD=4.64, non-responders M=17.3, SD=6.17. 
 
Hunnicutt-
Ferguson et 
al. (2012)b 
SG median pre-
gain session 1a 
15 (35.7%) 27 Sudden gain patients had significantly different rates of treatment response to non-sudden gain 
participants (X2=5.09, p<.05). 
 
 
Jordan et al. 
(2014) 
Week 4 NA NA Participants in both therapies showed clinically significant improvements on the QIDS at week 4 
(MCT d=.74, 95% CI [.30, 1.17]; CBT d=.73, 95% CI [.31, 1.14]).  
 
Lewis et al. 
(2012) 
Session 5 NA NA Around 76% of total symptom change was observed after intake, reaching 85.47% of total 
symptom change at session 5.  
 
Lutz et al. 
(2009) 
Week 8 99 (61.1%) 63 Class membership (early response and non-early response) was significantly associated with 
reliable improvement post-treatment (X2(9)=74.8, p<.001).  
 
Lutz et al. 
(2017) 
Week4 343 (83.9%) 66 Rapid early response effect size d=2.9; moderate early improvement d=1.19.  
 
 
Masterson et 
al. (2014) 
SG median pre-
gain session 2a 
17 (42.5%) 23 At post-treatment sudden gain groups had a mean PHQ score of M=5.3, SD=3.63, whereas non-
sudden gain participants had M=10.2, SD=6.8; t(35)=2.92, p=.006. 
 
Rabin et al. 
(1984) 
 
Week 3-4 NA NA For the majority of depressive symptoms, the largest changes occurred during the first 2 to 4 
sessions.  
Rubel et al. 
(2015) 
Session 3 396 (7.2%) 5088 Early responders showed the highest pre-post effect sizes (ds=1.88-2.16) and the highest share of 
reliably improved patients at post-treatment (90-93%).  
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Schibbye et 
al. (2014) 
Week 4 NA NA The disorder specific measures at week 4 explained variance in outcomes at post-treatment (panic 
disorder R2=.34, p<.01; depression R2=.41, p>.01; social anxiety disorder R2=.43, p<.01). 
 
Steidtmann 
et al. (2013) 
Week 6-8 NA NA Percentage of symptom reduction at weeks 4, 6 and 8 predicted post-treatment HRSD remission 
status in combined treatment (week 4: x2 = 6.26) and psychotherapy (week 4: x2 = 4.05). 
 
Steinman et 
al. (2013) 
SG session 2 19 (52.8%) 17 Cluster membership (sudden gains versus others) was a significant predictor of post-treatment 
outcomes, accounting for 25% of the variability in six-month follow-up scores.  
 
7DGLü et al. 
(2010) 
Week 2 95 (42.6%) 128 In both CBT and Sertraline, early response was a highly sensitive predictor of later stable 
response (76-82%) and stable remission (71-72%).   
 
Van et al. 
(2008) 
Week 8 109 (57.4%) 81 Early responders and non-responders in the psychotherapy condition were significantly different 
from each other in terms of final non-response (x2=5.069, p<.01), but this was not the case for 
remission rates (x2=.994, p=.319). In combined therapy, there were significant differences in 
terms of non-response (x2=16.019, p<.001) and remission (x2=12.435, p<.001). 
SG, sudden gain; NA, not available. Overall mean proportion of cases with early response across studies = 47.9% 
a Median pre-gain session refers to the therapy session immediately preceding the sudden gain (Tang & DeRubeis, 1999b)  
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Figure 1. PRISMA flow diagram of the systematic study selection 
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Figure 2. Random effects meta-analysis: post-treatment effect sizes comparing early responders vs. others 
 
